About Us
About Disruptive Pharma
Formulite®
Business model
The Board
Management
Investor Relations
Financial calender
Financial reports
Share information
Corporate governance
General meetings
Rights Issue 2025
Newsroom
Press releases
Analyses and presentations
Subscribe
Contact
Swe
Search
Advancing oral drug development with Formulite
®
Guard Therapeutics is acquiring Disruptive Pharma and changing its name to Disruptive Pharma AB
Read More
Latest Press Releases
Beyond bioavailability: from formulation to viable drug product
Read More
Beyond bioavailability: from formulation to viable drug product
Read More
Disruptive Pharma to attend CPHI Milan 2026
Read More
Press releases
09 Oct 2026
Beyond bioavailability: from formulation to viable drug product
Read More
09 Oct 2026
Beyond bioavailability: from formulation to viable drug product
Read More
29 Sep 2026
Disruptive Pharma to attend CPHI Milan 2026
Read More
22 Sep 2026
Disruptive Pharma divests GTX platform and retains rights to future royalty and milestone revenues
Read More
Show more
In focus
16 Sep 2025 / Presentation
CEO Tobias Agervald appears on BiotechTV
Read More
17 Oct 2024 / Presentation
Guard presents at Redeye Theme "Cardiovascular & Metabolic Diseases Event 2024"
Read More
23 Sep 2024 / Presentation
CEO Tobias Agervald appears on BiotechTV
Read More
19 Sep 2024 / Presentation
Presentation at Pareto Securities' 15th Annual Healthcare Conference
Read More
Show more
Upcoming events
12 Nov 2026
Interim Report January–September 2026
Read More
18 Feb 2027
Year-end Report 2026
Read More
Show more